Annual CFI
$184.15 M
+$324.11 M+231.57%
31 December 2023
Summary:
NovoCure Limited annual cash flow from investing activities is currently $184.15 million, with the most recent change of +$324.11 million (+231.57%) on 31 December 2023. During the last 3 years, it has risen by +$657.00 million (+138.94%). NVCR annual CFI is now at all-time high.NVCR Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$10.19 M
+$384.63 M+102.72%
30 September 2024
Summary:
NovoCure Limited quarterly cash flow from investing activities is currently $10.19 million, with the most recent change of +$384.63 million (+102.72%) on 30 September 2024. Over the past year, it has dropped by -$7.07 million (-40.94%). NVCR quarterly CFI is now -96.63% below its all-time high of $302.70 million, reached on 30 September 2021.NVCR Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$19.53 M
-$7.07 M-56.67%
30 September 2024
Summary:
NovoCure Limited TTM cash flow from investing activities is currently -$19.53 million, with the most recent change of -$7.07 million (-56.67%) on 30 September 2024. Over the past year, it has increased by +$22.88 million (+53.95%). NVCR TTM CFI is now -105.61% below its all-time high of $348.08 million, reached on 31 March 2024.NVCR TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVCR Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +231.6% | -40.9% | +54.0% |
| 3 y3 years | +138.9% | -96.6% | +92.5% |
| 5 y5 years | +3452.4% | +568.9% | -191.5% |
NVCR Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +138.9% | -96.6% | +102.0% | -105.6% | +96.2% |
| 5 y | 5 years | at high | +138.9% | -96.6% | +101.7% | -105.6% | +96.2% |
| alltime | all time | at high | +138.9% | -96.6% | +101.7% | -105.6% | +96.2% |
NovoCure Limited Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.19 M(-102.7%) | -$19.53 M(+56.7%) |
| June 2024 | - | -$374.44 M(-252.1%) | -$12.47 M(-103.6%) |
| Mar 2024 | - | $246.22 M(+150.0%) | $348.08 M(+89.0%) |
| Dec 2023 | $184.15 M(-231.6%) | $98.50 M(+470.7%) | $184.15 M(-534.2%) |
| Sept 2023 | - | $17.26 M(-224.2%) | -$42.41 M(-79.8%) |
| June 2023 | - | -$13.90 M(-116.9%) | -$209.91 M(+421.4%) |
| Mar 2023 | - | $82.29 M(-164.3%) | -$40.26 M(-71.2%) |
| Dec 2022 | -$139.96 M(-3.4%) | -$128.06 M(-14.8%) | -$139.96 M(-72.6%) |
| Sept 2022 | - | -$150.24 M(-196.5%) | -$510.99 M(+780.4%) |
| June 2022 | - | $155.76 M(-994.6%) | -$58.04 M(-73.2%) |
| Mar 2022 | - | -$17.41 M(-96.5%) | -$216.41 M(+49.4%) |
| Dec 2021 | -$144.83 M(-69.4%) | -$499.09 M(-264.9%) | -$144.83 M(-44.2%) |
| Sept 2021 | - | $302.70 M(<-9900.0%) | -$259.38 M(-37.5%) |
| June 2021 | - | -$2.62 M(-104.8%) | -$414.87 M(-0.2%) |
| Mar 2021 | - | $54.17 M(-108.8%) | -$415.56 M(-12.1%) |
| Dec 2020 | -$472.85 M(+815.2%) | -$613.64 M(-516.8%) | -$472.85 M(-602.8%) |
| Sept 2020 | - | $147.22 M(-4541.0%) | $94.03 M(-269.9%) |
| June 2020 | - | -$3.31 M(+6.5%) | -$55.36 M(+2.9%) |
| Mar 2020 | - | -$3.11 M(-93.3%) | -$53.79 M(+4.1%) |
| Dec 2019 | -$51.67 M | -$46.76 M(+2050.7%) | -$51.67 M(+671.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$2.17 M(+24.4%) | -$6.70 M(+21.1%) |
| June 2019 | - | -$1.75 M(+76.7%) | -$5.53 M(+19.6%) |
| Mar 2019 | - | -$989.00 K(-44.7%) | -$4.63 M(-15.8%) |
| Dec 2018 | -$5.49 M(-163.7%) | -$1.79 M(+78.0%) | -$5.49 M(-2.8%) |
| Sept 2018 | - | -$1.00 M(+19.4%) | -$5.65 M(-11.7%) |
| June 2018 | - | -$842.00 K(-54.7%) | -$6.40 M(+4.2%) |
| Mar 2018 | - | -$1.86 M(-4.6%) | -$6.14 M(-171.2%) |
| Dec 2017 | $8.63 M(-33.6%) | -$1.95 M(+11.0%) | $8.63 M(+20.4%) |
| Sept 2017 | - | -$1.75 M(+199.1%) | $7.16 M(+59.1%) |
| June 2017 | - | -$586.00 K(-104.5%) | $4.50 M(-393.2%) |
| Mar 2017 | - | $12.91 M(-478.7%) | -$1.54 M(-111.8%) |
| Dec 2016 | $13.00 M(-111.3%) | -$3.41 M(-22.7%) | $13.00 M(-111.9%) |
| Sept 2016 | - | -$4.41 M(-33.4%) | -$109.63 M(+40.8%) |
| June 2016 | - | -$6.63 M(-124.1%) | -$77.85 M(-28.7%) |
| Mar 2016 | - | $27.45 M(-121.8%) | -$109.13 M(-5.3%) |
| Dec 2015 | -$115.30 M(+149.7%) | -$126.04 M(-560.6%) | -$115.30 M(-1173.2%) |
| Sept 2015 | - | $27.36 M(-172.2%) | $10.74 M(-164.6%) |
| June 2015 | - | -$37.91 M(-278.1%) | -$16.62 M(-178.1%) |
| Mar 2015 | - | $21.28 M | $21.28 M |
| Dec 2014 | -$46.18 M(-544.0%) | - | - |
| Dec 2013 | $10.40 M | - | - |
FAQ
- What is NovoCure Limited annual cash flow from investing activities?
- What is the all time high annual CFI for NovoCure Limited?
- What is NovoCure Limited annual CFI year-on-year change?
- What is NovoCure Limited quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for NovoCure Limited?
- What is NovoCure Limited quarterly CFI year-on-year change?
- What is NovoCure Limited TTM cash flow from investing activities?
- What is the all time high TTM CFI for NovoCure Limited?
- What is NovoCure Limited TTM CFI year-on-year change?
What is NovoCure Limited annual cash flow from investing activities?
The current annual CFI of NVCR is $184.15 M
What is the all time high annual CFI for NovoCure Limited?
NovoCure Limited all-time high annual cash flow from investing activities is $184.15 M
What is NovoCure Limited annual CFI year-on-year change?
Over the past year, NVCR annual cash flow from investing activities has changed by +$324.11 M (+231.57%)
What is NovoCure Limited quarterly cash flow from investing activities?
The current quarterly CFI of NVCR is $10.19 M
What is the all time high quarterly CFI for NovoCure Limited?
NovoCure Limited all-time high quarterly cash flow from investing activities is $302.70 M
What is NovoCure Limited quarterly CFI year-on-year change?
Over the past year, NVCR quarterly cash flow from investing activities has changed by -$7.07 M (-40.94%)
What is NovoCure Limited TTM cash flow from investing activities?
The current TTM CFI of NVCR is -$19.53 M
What is the all time high TTM CFI for NovoCure Limited?
NovoCure Limited all-time high TTM cash flow from investing activities is $348.08 M
What is NovoCure Limited TTM CFI year-on-year change?
Over the past year, NVCR TTM cash flow from investing activities has changed by +$22.88 M (+53.95%)